Kevin Codorniz, MD
Endocrinology, Diabetes & Metabolism · Loma Linda, CANPI 1871702316
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Dexcom, Inc. accounts for 64.8% of it on its own, with 3 other manufacturers making up the rest. 2024 is the largest year on record at $222, 4.8 times the $47 reported in 2019. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in CA, where the typical reported total is $1,096.
Across 30 payments — averaging $11.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$220
- Medtronic$76
- Mannkind Corporation$30
- Insulet Corporation$15
Across 71 payments — averaging $14,320 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$676K
- Mannkind Corporation$341K
What the payments were for
- Food & beverage$340100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 25 | $220 |
| Medtronic(2 entities) | 3 | $76 |
| Mannkind Corporation | 1 | $30 |
| Insulet Corporation | 1 | $15 |
How this compares
$340 in reported general payments places this provider in the 25th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 97 | $117,952 |
| OzempicSemaglutide | 75 | $108,533 |
| JardianceEmpagliflozin | 63 | $74,247 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $26,338 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 21 | $16,013 |
| JanuviaSitagliptin Phosphate | 15 | $15,867 |
| Humalog Kwikpen U-100Insulin Lispro | 44 | $13,628 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $8,094 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 21 | $7,010 |
| Desmopressin Acetate | 48 | $5,685 |
| Novolog FlexpenInsulin Aspart | 28 | $5,571 |
| HumalogInsulin Lispro | 15 | $5,016 |
| Admelog SolostarInsulin Lispro | 26 | $4,579 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $4,548 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 35 | $3,623 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Loma Linda
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.